Company Filing History:
Years Active: 1993-2001
Title: Martin S. Springer: Innovator in Chemokine Receptor Research
Introduction
Martin S. Springer is a notable inventor based in Westfield, NJ (US). He has made significant contributions to the field of chemokine receptor research, holding a total of 6 patents. His work has implications for the treatment of various atopic conditions, showcasing his dedication to advancing medical science.
Latest Patents
One of his latest patents involves the eosinophil eotaxin receptor. This receptor has been isolated, cloned, and sequenced, and is recognized as a human β-chemokine receptor designated as "CC CKR3". The eosinophil eotaxin receptor may be utilized to screen and identify compounds that bind to it, which could be beneficial in treating and preventing atopic conditions such as allergic rhinitis, dermatitis, conjunctivitis, and particularly bronchial asthma. Another significant patent focuses on spiro-substituted azacycles as modulators of chemokine receptor activity. This invention presents spiro-substituted azacycles of a specific formula, which are useful in modulating various chemokine receptors, including CCR-1, CCR-2, CCR-2A, CCR-2B, CCR-3, CCR-4, CCR-5, CXCR-3, and CXCR-4.
Career Highlights
Martin S. Springer is currently associated with Merck & Co., Inc., where he continues to contribute to innovative research in his field. His work has not only advanced scientific understanding but has also paved the way for potential therapeutic applications.
Collaborations
Some of his notable coworkers include Sander G. Mills and Malcolm MacCoss, who have collaborated with him on various research projects.
Conclusion
Martin S. Springer stands out as a prominent inventor in the realm of chemokine receptor research, with a focus on developing innovative solutions for atopic conditions. His contributions are vital to the ongoing advancements in medical science.